GleamWall
中文EN

FTH Faeth Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1829802 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-775.6%
TTM EPS YoY-17.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-229.6%
ROA-204.7%
ROIC (approx.)-214.2%
Asset turnover—

Leverage & solvency

Liabilities / assets6.2%
Debt / equity0.00x
Current ratio16.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.20x
Accruals ratio-162.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
SG&A expense$10.35M$9.21M$19.71M$2.79M$2.31M$2.67M$3.55M$2.83M
Operating income-$22.09M-$18.39M-$170.63M-$4.96M-$4.85M-$5.21M-$7.27M-$8.27M
Interest expense———$3,000$6,000$10,000$13,000$17,000
Income tax$0$0$0$0$0$0$0$0
Net income-$20.40M-$16.01M-$170.24M-$4.72M-$4.57M-$4.94M-$6.86M-$7.77M
EBITDA-$22.07M-$18.36M-$170.60M-$4.93M-$4.82M-$5.17M-$7.24M-$8.13M
EPS (basic)-0.79-2.84-131.45—-3.62-3.91-5.45—
EPS (diluted)-0.79-2.84-131.45—-3.62-3.91-5.45—
Weighted avg. shares (diluted)25.84M5.64M1.30M—1.26M1.26M1.26M—
Balance sheet
Cash & equivalents$14.18M$26.90M$152.32M$8.67M$10.56M$12.56M$9.88M$9.99M
Short-term investments$160.62M$159.54M$50.47M$12.52M$14.48M$16.07M$24.45M$31.34M
Current assets$177.84M$188.66M$204.23M$21.51M$25.79M$29.57M$35.68M$41.93M
PP&E, net$1,000$44,000$69,000$82,000$112,000$143,000$159,000$417,000
Goodwill$0$0$0—————
Total assets$178.95M$189.31M$205.38M$22.90M$27.59M$31.78M$38.27M$45.36M
Current liabilities$11.03M$9.58M$14.19M$4.25M$4.44M$3.87M$5.23M$5.45M
Total liabilities$11.09M$9.58M$14.19M$4.31M$4.58M$4.47M$6.29M$6.97M
Shareholders' equity$161.10M$172.96M-$137.29M$18.59M$23.01M$27.31M$31.99M$38.39M
Shares outstanding25.84M25.83M1.34M1.26M1.26M1.26M25.21M1.26M
Cash flow statement
Operating cash flow-$13.00M-$15.67M-$10.73M-$3.86M-$3.59M-$5.91M-$7.09M-$5.79M
Capital expenditure$3,000$0$6,000$0$0$16,000$0$0
Free cash flow-$13.01M-$15.67M-$10.74M-$3.86M-$3.59M-$5.92M-$7.09M-$5.79M
Investing cash flow$175,000-$108.07M-$31.44M$2.08M$1.74M$8.76M$7.19M-$3.15M
Financing cash flow$104,000-$1.68M$185.83M-$111,000-$152,000-$168,000-$214,000-$194,000
Depreciation & amortization$17,000$25,000$29,000$30,000$30,000$32,000$30,000$139,000
Stock-based compensation$8.52M$4.48M$12.90M$295,000$254,000$264,000$461,000$391,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.